Navigation Links
Cancer Research Institute invests $450k in Oncovir to manufacture powerful immune stimulant
Date:1/21/2011

eement with Oncovir.

"The CVC was established on the fundamental premise that cancer vaccines must include multiple components, including an antigenic target or targets, a delivery system, an immunological stimulant, and a modulator of immunosuppression, or checkpoint blockade, to ensure that the anti-tumor immune response, once aroused, does not shut down prematurely," says Lloyd J. Old, M.D., director of the CRI Scientific Advisory Council and director of the CVC. "Providing funding that will enable a large quantity of clinical grade Poly-ICLC to be manufactured is essential to furthering both Oncovir's and our program's clinical research objectives. Specifically, having a supply of Hiltonol under CVC control will make it possible for our investigators to identify its optimal use within the context of cancer vaccines, particularly in combination with other critical agents, such as antibodies that have the capacity to neutralize cancer-induced immunosuppression. The partnership with Oncovir brings us one step closer to an optimally effective therapeutic cancer vaccine for patients."

As part of its ongoing collaborative program to make Hiltonol available for a variety of therapeutic applications, Oncovir plans to continue to distribute Hiltonol, including the remaining portion of the CVAF-supported batch, to qualified scientists and companies testing next-generation cancer vaccines, as well as to scientists testing promising new immunologic therapies for HIV, malaria, influenza, SARS, hepatitis, and other infectious diseases.

"The CVAF strategy was designed to achieve two principal goalsto increase the number of promising vaccine components in global development, and to facilitate clinical research that will accelerate the refinement of powerful, multi-component cancer vaccines," says Adam Kolom, director of CVAF. "This new partnership with Oncovir will help us advance both, while also adding a valuable agent to our license and intell
'/>"/>

Contact: Brian M. Brewer
bbrewer@cancerresearch.org
212-688-7515
Cancer Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Go figure: Math model may help researchers with stem cell, cancer therapies
2. Uncovering the genetics of prostate cancer
3. Roundworm unlocks pancreatic cancer pathway
4. Researchers unlock how progesterone increases breast cancer risk
5. MicroRNA suppresses prostate cancer stem cells and metastasis
6. Researchers learn why PSA levels reflect prostate cancer progression
7. TGen and Genomic Health Inc. discover genes affecting cancer drug
8. Measles virus, a weapon against cancer?
9. Study identifies new genetic signatures of breast cancer drug resistance
10. An earlier start on diagnosing breast, prostate cancers
11. Early investigations promising for detecting metastatic breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... puberty is influenced by ,imprinted genes,a subset of genes whose ... This is the first evidence that imprinted genes can control ... study were published today in the journal Nature . ... a marker for the timing of puberty in females. ... girls, is an inherited trait, and is linked to breast ...
(Date:7/25/2014)... a molecular testing panel developed at UPMC greatly ... surgery for patients with thyroid nodules and cancer, ... Institute (UPCI), partner with UPMC CancerCenter., The test, ... other diagnostic testing agencies, improved the chances of ... percent, according to the study published this month ...
(Date:7/25/2014)... July 25, 2014 Biometrics industry ... turning to digital technology for online & commerce payments ... Inc. (NASDAQ: GOOG ), LifeLock Inc. (NYSE: ... V ), Apple Inc. (NASDAQ: AAPL ) ... (OTCQB: NXTD) a biometric authentication company focused on the ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 2Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 3Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 4Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 5Consumer Needs for Identity Theft Security Grows with Popularity of Latest Smart Technology Products - Biometrically Secure Digital Wallet to Replace Credit Card Dependency 6
... the AAAS Symposium, "Emerging Threats and Research Challenges ... 10:30. William Laurance, senior staff scientist ... moderator, recently co-organized a major event, "Debating the ... Natural History in Washington, which was featured in ...
... used in biomedicine and engineering likely won,t cause unexpected ... presented today. The result should allay fears that cells ... finest silica nanomaterials in industrial or commercial applications. ... size doesn,t matter, by using total surface area as ...
... simple, chemical materials model may lead to a better ... according to a Penn State researcher. "Cells are interesting ... the cytoplasm, and while it is thought to be ... how this organization is achieved," said Christine Keating, associate ...
Cached Biology News:AAAS Symposium: Emerging threats to tropical, temperate and ocean ecosystems 2Nanoparticle toxicity doesn't get wacky at the smallest sizes 2Nanoparticle toxicity doesn't get wacky at the smallest sizes 3Artificial cells, simple model for complex structure 2Artificial cells, simple model for complex structure 3
(Date:7/25/2014)... 25, 2014 WABC Radio show out of ... with Lorry Young will be hosting California-based Vet-Stem, Inc.’s Founder ... cell therapy in pets. Dr. Harman first visited the ... cell therapy for pets suffering from osteoarthritis and other degenerative ... Medicine industry forward. , Young has invited Dr. Harman back ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
(Date:7/24/2014)... -- A novel combination of microscopy and data processing ... Ridge National Laboratory an unprecedented look at the surface ... electrochemical properties. , The research team led by ... of a perovskite manganite, a complex material that exhibits ... understand surface behavior could benefit researchers who are interested ...
(Date:7/24/2014)... July 24, 2014  ECC West Africa, LLC (ECC) ... with University College Hospital (UCH) Ibadan Board of ... to finance, design, construct, and operate and maintain a ... . Under the first of the 4-phase project, ... and funding applications. UCH Ibadan intends to finance and ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3ORNL study reveals new characteristics of complex oxide surfaces 2ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... ARIUS Research Inc., (TSX:,ARI), a biotechnology company ... therapeutics, today announced its financial and operational,results ... ended May 31st, 2008., "Throughout the ... moving,ARIUS, anti-cancer antibodies towards human clinical trial. ...
... , The white blood cells in our body combat ... leukemia, the formation of white blood cells is disturbed: ... multiply out of control without fully maturing. This process ... more susceptible to infections. T-ALL, a particular form of ...
... electronic device is an important step toward helping astronomers ... universe. This invisible light makes up 98% of the ... insights into the earliest stages of star and galaxy ... new circuit, developed by physicsts at Rutgers University, NASA,s ...
Cached Biology Technology:ARIUS announces second quarter fiscal 2008 financial results 2ARIUS announces second quarter fiscal 2008 financial results 3ARIUS announces second quarter fiscal 2008 financial results 4ARIUS announces second quarter fiscal 2008 financial results 5ARIUS announces second quarter fiscal 2008 financial results 6ARIUS announces second quarter fiscal 2008 financial results 7ARIUS announces second quarter fiscal 2008 financial results 8ARIUS announces second quarter fiscal 2008 financial results 9ARIUS announces second quarter fiscal 2008 financial results 10ARIUS announces second quarter fiscal 2008 financial results 11ARIUS announces second quarter fiscal 2008 financial results 12ARIUS announces second quarter fiscal 2008 financial results 13ARIUS announces second quarter fiscal 2008 financial results 14ARIUS announces second quarter fiscal 2008 financial results 15Not the protein, but its location in the cell, determines the onset of leukemia 2Nano-sized electronic circuit promises bright view of early universe 2Nano-sized electronic circuit promises bright view of early universe 3
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Human VEGF-D Biotinylated MAb (Clone 78923)...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Biology Products: